Scientific rationale for developing potent RBD-based vaccines targeting COVID-19
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Scientific rationale for developing potent RBD-based vaccines targeting COVID-19
Authors
Keywords
-
Journal
npj Vaccines
Volume 6, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2021-10-28
DOI
10.1038/s41541-021-00393-6
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Rapid Development of SARS-CoV-2 Spike Protein Receptor-Binding Domain Self-Assembled Nanoparticle Vaccine Candidates
- (2021) Yin-Feng Kang et al. ACS Nano
- Design of SARS-CoV-2 hFc-Conjugated Receptor-Binding Domain mRNA Vaccine Delivered via Lipid Nanoparticles
- (2021) Uri Elia et al. ACS Nano
- Evolution of antibody immunity to SARS-CoV-2
- (2021) Christian Gaebler et al. NATURE
- Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection
- (2021) Jennifer M. Dan et al. SCIENCE
- A COVID-19 vaccine candidate using SpyCatcher multimerization of the SARS-CoV-2 spike protein receptor-binding domain induces potent neutralising antibody responses
- (2021) Tiong Kit Tan et al. Nature Communications
- The antigenic anatomy of SARS-CoV-2 receptor binding domain
- (2021) Wanwisa Dejnirattisai et al. CELL
- Comprehensive mapping of mutations in the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human plasma antibodies
- (2021) Allison J. Greaney et al. Cell Host & Microbe
- Ferritin nanoparticle-based SARS-CoV-2 RBD vaccine induces a persistent antibody response and long-term memory in mice
- (2021) Wenjun Wang et al. Cellular & Molecular Immunology
- Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials
- (2021) Merryn Voysey et al. LANCET
- Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial
- (2021) Zhiwei Wu et al. LANCET INFECTIOUS DISEASES
- Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial
- (2021) Raches Ella et al. LANCET INFECTIOUS DISEASES
- Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies
- (2021) Dami A. Collier et al. NATURE
- Serum Neutralizing Activity Elicited by mRNA-1273 Vaccine — Preliminary Report
- (2021) Kai Wu et al. NEW ENGLAND JOURNAL OF MEDICINE
- Recurrent deletions in the SARS-CoV-2 spike glycoprotein drive antibody escape
- (2021) Kevin R. McCarthy et al. SCIENCE
- Development of Spike Receptor-Binding Domain Nanoparticles as a Vaccine Candidate against SARS-CoV-2 Infection in Ferrets
- (2021) Young-Il Kim et al. mBio
- A Novel DNA Vaccine Against SARS-CoV-2 Encoding a Chimeric Protein of Its Receptor-Binding Domain (RBD) Fused to the Amino-Terminal Region of Hepatitis B Virus preS1 With a W4P Mutation
- (2021) Hyein Jeong et al. Frontiers in Immunology
- Immunogenicity of clinically relevant SARS-CoV-2 vaccines in non-human primates and humans
- (2021) P. J. Klasse et al. Science Advances
- Process development and scale-up optimization of the SARS-CoV-2 receptor binding domain–based vaccine candidate, RBD219-N1C1
- (2021) Jungsoon Lee et al. APPLIED MICROBIOLOGY AND BIOTECHNOLOGY
- N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2
- (2021) Matthew McCallum et al. CELL
- Antibody evasion by the P.1 strain of SARS-CoV-2
- (2021) Wanwisa Dejnirattisai et al. CELL
- A combination of cross-neutralizing antibodies synergizes to prevent SARS-CoV-2 and SARS-CoV pseudovirus infection
- (2021) Hejun Liu et al. Cell Host & Microbe
- WHO International Standard for anti-SARS-CoV-2 immunoglobulin
- (2021) Paul A Kristiansen et al. LANCET
- Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials
- (2021) Shilong Yang et al. LANCET INFECTIOUS DISEASES
- Adjuvanting a subunit COVID-19 vaccine to induce protective immunity
- (2021) Prabhu S. Arunachalam et al. NATURE
- Escape of SARS-CoV-2 501Y.V2 from neutralization by convalescent plasma
- (2021) Sandile Cele et al. NATURE
- Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection
- (2021) David S. Khoury et al. NATURE MEDICINE
- Safety and immunogenicity of the SARS-CoV-2 BNT162b1 mRNA vaccine in younger and older Chinese adults: a randomized, placebo-controlled, double-blind phase 1 study
- (2021) Jingxin Li et al. NATURE MEDICINE
- Cross-Reactive Neutralizing Antibody Responses Elicited by SARS-CoV-2 501Y.V2 (B.1.351)
- (2021) Thandeka Moyo-Gwete et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19
- (2021) Jerald Sadoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant
- (2021) Vivek Shinde et al. NEW ENGLAND JOURNAL OF MEDICINE
- Clonal analysis of immunodominance and cross-reactivity of the CD4 T cell response to SARS-CoV-2
- (2021) Jun Siong Low et al. SCIENCE
- SARS‑CoV-2 RBD219-N1C1: A yeast-expressed SARS-CoV-2 recombinant receptor-binding domain candidate vaccine stimulates virus neutralizing antibodies and T-cell immunity in mice
- (2021) Jeroen Pollet et al. Human Vaccines & Immunotherapeutics
- SARS-CoV-2 evolution and vaccines: cause for concern?
- (2021) Thomas C Williams et al. Lancet Respiratory Medicine
- Single-component, self-assembling, protein nanoparticles presenting the receptor binding domain and stabilized spike as SARS-CoV-2 vaccine candidates
- (2021) Linling He et al. Science Advances
- Distinct antibody and memory B cell responses in SARS-CoV-2 naïve and recovered individuals following mRNA vaccination
- (2021) Rishi R. Goel et al. Science Immunology
- Development of a Vaccine against SARS-CoV-2 Based on the Receptor-Binding Domain Displayed on Virus-Like Particles
- (2021) Lisha Zha et al. Vaccines
- Genetic modification to design a stable yeast-expressed recombinant SARS-CoV-2 receptor binding domain as a COVID-19 vaccine candidate
- (2021) Wen-Hsiang Chen et al. BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS
- Elicitation of broadly protective sarbecovirus immunity by receptor-binding domain nanoparticle vaccines
- (2021) Alexandra C. Walls et al. CELL
- SARS-CoV-2 mRNA vaccination induces functionally diverse antibodies to NTD, RBD, and S2
- (2021) Fatima Amanat et al. CELL
- Interferon-armed RBD dimer enhances the immunogenicity of RBD for sterilizing immunity against SARS-CoV-2
- (2021) Shiyu Sun et al. CELL RESEARCH
- The potential clinical utility of measuring severe acute respiratory syndrome coronavirus 2-specific T-cell responses
- (2021) Delia Goletti et al. CLINICAL MICROBIOLOGY AND INFECTION
- Affinity maturation of SARS-CoV-2 neutralizing antibodies confers potency, breadth, and resilience to viral escape mutations
- (2021) Frauke Muecksch et al. IMMUNITY
- Evaluation of Cell-Based and Surrogate SARS-CoV-2 Neutralization Assays
- (2021) Anton M. Sholukh et al. JOURNAL OF CLINICAL MICROBIOLOGY
- Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humans
- (2021) Galit Alter et al. NATURE
- Broad sarbecovirus neutralization by a human monoclonal antibody
- (2021) M. Alejandra Tortorici et al. NATURE
- SARS-CoV-2 RBD antibodies that maximize breadth and resistance to escape
- (2021) Tyler N. Starr et al. NATURE
- CD8+ T cells contribute to survival in patients with COVID-19 and hematologic cancer
- (2021) Erin M. Bange et al. NATURE MEDICINE
- SARS-CoV-2 variants, spike mutations and immune escape
- (2021) William T. Harvey et al. NATURE REVIEWS MICROBIOLOGY
- Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine
- (2021) Paul T. Heath et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy and breadth of adjuvanted SARS-CoV-2 receptor-binding domain nanoparticle vaccine in macaques
- (2021) Hannah A. D. King et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- SARS-CoV-2 escape from a highly neutralizing COVID-19 convalescent plasma
- (2021) Emanuele Andreano et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Engineered SARS-CoV-2 receptor binding domain improves manufacturability in yeast and immunogenicity in mice
- (2021) Neil C. Dalvie et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Ultrapotent antibodies against diverse and highly transmissible SARS-CoV-2 variants
- (2021) Lingshu Wang et al. SCIENCE
- SARS-CoV-2 immune evasion by the B.1.427/B.1.429 variant of concern
- (2021) Matthew McCallum et al. SCIENCE
- Antibodies elicited by mRNA-1273 vaccination bind more broadly to the receptor binding domain than do those from SARS-CoV-2 infection
- (2021) Allison J. Greaney et al. Science Translational Medicine
- Intranasal ChAdOx1 nCoV-19/AZD1222 vaccination reduces viral shedding after SARS-CoV-2 D614G challenge in preclinical models
- (2021) Neeltje van Doremalen et al. Science Translational Medicine
- Structural basis for accommodation of emerging B.1.351 and B.1.1.7 variants by two potent SARS-CoV-2 neutralizing antibodies
- (2021) Gabriele Cerutti et al. STRUCTURE
- Evidence for antibody as a protective correlate for COVID-19 vaccines
- (2021) Kristen A. Earle et al. VACCINE
- Immunogenicity and Protective Efficacy of a Highly Thermotolerant, Trimeric SARS-CoV-2 Receptor Binding Domain Derivative
- (2021) Sameer Kumar Malladi et al. ACS Infectious Diseases
- Outbreak of SARS-CoV-2 Infections, Including COVID-19 Vaccine Breakthrough Infections, Associated with Large Public Gatherings — Barnstable County, Massachusetts, July 2021
- (2021) Catherine M. Brown et al. MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
- Yeast-produced RBD-based recombinant protein vaccines elicit broadly neutralizing antibodies and durable protective immunity against SARS-CoV-2 infection
- (2021) Jinkai Zang et al. Cell Discovery
- Intranasal Administration of RBD Nanoparticles Confers Induction of Mucosal and Systemic Immunity against SARS-CoV-2
- (2021) Tuksin Jearanaiwitayakul et al. Vaccines
- Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
- (2020) Daniel Wrapp et al. SCIENCE
- Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein
- (2020) Alexandra C. Walls et al. CELL
- Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody
- (2020) Dora Pinto et al. NATURE
- Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor
- (2020) Jun Lan et al. NATURE
- A Universal Design of Betacoronavirus Vaccines against COVID-19, MERS, and SARS
- (2020) Lianpan Dai et al. CELL
- A Thermostable mRNA Vaccine against COVID-19
- (2020) Na-Na Zhang et al. CELL
- A novel receptor-binding domain (RBD)-based mRNA vaccine against SARS-CoV-2
- (2020) Wanbo Tai et al. CELL RESEARCH
- A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity
- (2020) Jingyun Yang et al. NATURE
- Phase 1/2 study of COVID-19 RNA vaccine BNT162b1 in adults
- (2020) Mark J. Mulligan et al. NATURE
- Convergent antibody responses to SARS-CoV-2 in convalescent individuals
- (2020) Davide F. Robbiani et al. NATURE
- Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates
- (2020) Kizzmekia S. Corbett et al. NEW ENGLAND JOURNAL OF MEDICINE
- Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model
- (2020) Thomas F. Rogers et al. SCIENCE
- Structure-based design of prefusion-stabilized SARS-CoV-2 spikes
- (2020) Ching-Lin Hsieh et al. SCIENCE
- Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology
- (2020) Luca Piccoli et al. CELL
- SARS-CoV-2 immunity: review and applications to phase 3 vaccine candidates
- (2020) Gregory A Poland et al. LANCET
- SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies
- (2020) Christopher O. Barnes et al. NATURE
- COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses
- (2020) Ugur Sahin et al. NATURE
- Broad and strong memory CD4+ and CD8+ T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19
- (2020) Yanchun Peng et al. NATURE IMMUNOLOGY
- Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates
- (2020) Edward E. Walsh et al. NEW ENGLAND JOURNAL OF MEDICINE
- Phase 1–2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine
- (2020) Cheryl Keech et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ultrapotent human antibodies protect against SARS-CoV-2 challenge via multiple mechanisms
- (2020) M. Alejandra Tortorici et al. SCIENCE
- Double-Blind, Randomized, Placebo-Controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of treating Healthcare Professionals with the Adsorbed COVID-19 (Inactivated) Vaccine Manufactured by Sinovac – PROFISCOV: A structured summary of a study protocol for a randomised controlled trial
- (2020) Ricardo Palacios et al. Trials
- Nanoparticle Vaccines Based on the Receptor Binding Domain (RBD) and Heptad Repeat (HR) of SARS-CoV-2 Elicit Robust Protective Immune Responses
- (2020) Xiancai Ma et al. IMMUNITY
- Correlates of protection against SARS-CoV-2 in rhesus macaques
- (2020) Katherine McMahan et al. NATURE
- Enhanced SARS-CoV-2 neutralization by dimeric IgA
- (2020) Zijun Wang et al. Science Translational Medicine
- Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial
- (2020) Yanjun Zhang et al. LANCET INFECTIOUS DISEASES
- Updates on immunologic correlates of vaccine-induced protection
- (2019) Stanley A. Plotkin VACCINE
- Correlates of Protection Induced by Vaccination
- (2010) S. A. Plotkin Clinical and Vaccine Immunology
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now